Exploring the impact of dexamethasone on gene regulation in myeloma cells

Area of Science:

• Genomics
• Molecular Biology
• Cancer Research

Background:

• Glucocorticoids like dexamethasone (Dex) are crucial for multiple myeloma treatment.
• Patient relapse despite initial Dex benefits highlights the need to understand resistance mechanisms.
• The precise molecular basis of dexamethasone efficacy and resistance in myeloma remains unclear.

Purpose of the Study:

• To elucidate the genomic and epigenomic responses to dexamethasone in multiple myeloma cells.
• To identify key regulatory elements and molecular players involved in dexamethasone sensitivity and resistance.
• To investigate the role of enhancer activity, cohesin, and CTCF in dexamethasone-induced gene expression and cell fate.

Main Methods:

• Generation of bulk and single-cell multi-omics data (genomics, epigenomics, transcriptomics).
• High-resolution contact mapping of active enhancers and target genes.
• Analysis of gene-specific networks and regulatory element accessibility.

Main Results:

• A subset of glucocorticoid receptor-binding sites drives enhancer activity, gene interactions, and transcription upon Dex exposure.
• A key enhancer, enriched in cohesin (RAD21), becomes more accessible after Dex treatment.
• CTCF-cohesin complex and synchronized regulatory openings are vital for efficient gene transcription.
• Epigenomic changes correlate with cell-to-cell transcriptional heterogeneity, affecting apoptosis-related genes like BCL2L11 (BIM) and CXCR4.

Conclusions:

• This study reveals novel molecular mechanisms underlying dexamethasone response and escape in multiple myeloma.
• Understanding these epigenomic dynamics, including cohesin and CTCF roles, is critical for developing strategies to overcome treatment resistance.
• The identified heterogeneity in gene regulation contributes to differential cell responses and therapeutic outcomes.